Stratify Genomics

Stratify Genomics commercializes the Prompt Prostate Genetic Score (PGS), a non-invasive cheek swab test that assesses a man’s genetic predisposition to prostate cancer using a patented, SNP-based assay. The test provides personalized lifetime risk assessment and guides clinicians on individualized screening frequency, aiming to improve early detection and reduce unnecessary biopsies or PSA screenings. Prompt PGS is validated in large clinical trials and is positioned as more efficient than annual PSA or family history-based screening for detecting prostate cancer. The company’s focus is on improving population health by enabling risk-stratified, personalized cancer screening.